Boost Study 31380 (mHealth)

July 31, 2023 updated by: NXTech

BoostOne Study (MHealth)

The purpose of this research is to examine the potential for a new software-based behavioral support approach, for individuals with opioid use disorder, as an addition to usual care.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The purpose of this study is to examine the potential for a novel computer-based approach to mitigate the symptoms of opioid use disorder as part of a comprehensive treatment program. The study is designed as a single-arm field-test of cognitive training for individuals under supervised medical treatment for opioid use disorder. A custom and proprietary smartphone application comprises the intervention available to enrolled subjects for interaction over the study period. Commercial mobile devices serve as information presentation and data recording instruments. Additional outcome measures incorporate subject-reported data.

Study Type

Interventional

Enrollment (Actual)

43

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Astoria, New York, United States, 11106
        • PHNY

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18-65 years
  • Diagnosis of opioid use disorder
  • Experiencing symptoms multiple times per week
  • Familiar with smartphone usage

Exclusion Criteria:

- None specified

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental
MHealth group
Mobile application

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Interaction Engagement, as Assessed by Measured Usage Time
Time Frame: Total at 8 weeks
Usage Time (units in minutes, range 0 to unbound)
Total at 8 weeks
Interaction Engagement, as Assessed by Interactions Completed
Time Frame: Total at 8 weeks
Interactions Completed (units in counts of interactions, range 0 to unbound)
Total at 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intervention Usability Rating, as Assessed by Likert User Experience Scale
Time Frame: Score at 8 weeks
Subjective scoring of design and function usability, Likert User Experience Scale (score range 1-5, higher better)
Score at 8 weeks
Treatment Progress Measure, as Assessed by TEA Score
Time Frame: Change over 8 weeks, assessed weekly (week 1 to week 8 change)
Patient-centered instrument for evaluating progress in recovery from addiction, TEA Score (scale range 4 to 40, higher better)
Change over 8 weeks, assessed weekly (week 1 to week 8 change)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Alexis Vien, MD, PHNY

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 18, 2022

Primary Completion (Actual)

March 1, 2023

Study Completion (Actual)

March 30, 2023

Study Registration Dates

First Submitted

January 31, 2023

First Submitted That Met QC Criteria

March 3, 2023

First Posted (Actual)

March 7, 2023

Study Record Updates

Last Update Posted (Actual)

August 1, 2023

Last Update Submitted That Met QC Criteria

July 31, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • NX-31380

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Addiction

Clinical Trials on MHealth

3
Subscribe